Nasdaq

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

VANFLYTA is approved in the U.S. in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, ...
News Medical

Invivoscribe receives FDA approval for the LeukoStrat CDx FLT3 mutation assay companion diagnostic test for the selection of patients for Rydapt

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® ...
Healthline

Targeted Therapy to Treat Acute Myeloid Leukemia with FLT3 Mutation: How It Works, Side Effects, and More

Innovative research has helped doctors learn more about how cancer cells grow and why it’s a bit different in every person. This has led to the development of drugs that target specific molecules that ...
Seeking Alpha

VANFLYTA® is Now Approved in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML

TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and ...